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2008 Presidential Address:
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Aravinda Chakravarti1,*Aravinda ChakravartiGood afternoon, and welcome to the 58th annual
meeting of The American Society of Human Genetics in
historic Philadelphia. I am Aravinda Chakravarti, your
Society’s President, and I am honored and proud to have
represented you this year. I want to spend my time with
you today reﬂecting not on what we have already accom-
plished, which is substantial, but on the future of our
science: our drive toward a Principia Genetica.1
We live in very historic times. Each generation believes
this dearly, but our times are special indeed. As all of you
know, we had a national election in the United States
last week. The campaigning is ﬁnally over; Americans
have overwhelmingly elected Barack Obama as President,
and we stand many inches taller in having overcome the
prejudices of our recent past to elect a person of color to
the highest ofﬁce in the land. The President-elect, alluding
to themomentous changes of this day and our times, said:1
‘‘A man touched down on the moon, a wall came
down in Berlin, a world was connected by our own
science and imagination.’’1McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University
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the importance of connecting science with our imagina-
tion as a central agent of change in our world, and so
I have hope that science will return to its central position
in the life of this great country. For us as human
geneticists, this annual meeting is our forum to connect
science with our imagination, thereby creating new possi-
bilities.The American Society of Human Genetics
Ours is a young Society at 60 years, but this is quite
a long haul in the history of genetics. Our Society was
born on September 11th, 1948, starting with the presi-
dency of the great geneticist Hermann Joseph Muller.2
We are fortunate to have a well-documented birth, and
the papers incorporating the organization with its list
of members are available within our archives.2 These
members could not have envisioned the future progress
in our science, the open culture of our work, or the bor-
derless collaborations that have ensued. Today, The
American Society of Human Genetics can no longer
afford to be cast in terms of its geography but needs to
be cast by its science and its future. Full membership is
now open to all individuals around the world based on
their professional interest. They can, and we expect
them to, participate in every aspect of the academic life
of this Society and engage in ventures that use the crea-
tivity among all our members. I take our Society’s motto
of ‘‘Discover-Educate-Advocate’’ seriously: consequently,
we need to take leadership in promoting human genetics
worldwide. As a start, our Society is contemplating meet-
ings beyond our national assemblage and beyond North
American shores, including smaller meetings on focused
topics in partnerships with other organizations. As an
inaugural, in March 2009, The American Society of
Human Genetics will organize and host, in collaboration
with HUGO and the Nature Publishing Group, an interna-
tional meeting in Singapore entitled Genetics and Geno-
mics of Infectious Diseases.3 I hope that many of you will
attend, send your trainees, or recommend the meeting
to your colleagues and collaborators. I also hope that
these meetings will bring in new members and cement
the connections between old members, here and around
the world.School of Medicine, Baltimore, MD 21287, USA
Genetics. All rights reserved.
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The Logic of Human Genetics
The theme of my talk is ‘‘Our future science,’’ and I have
called this Principia Genetica, in ﬂattery and tribute to the
Principia Mathematica, published as three books in the early
part of the twentieth century.4 These were monumental
works, compiled, written, sweated, and argued over by
Alfred North Whitehead and Bertrand Russell. Such was
their effort that a fourth book on geometry never material-
ized because they were intellectually exhausted. They suc-
ceeded in showing that all pure mathematics followed
from purely logical premises, using only concepts deﬁned
in logical terms. These books are important and legendary
not only in mathematics, but stand as one of the pinnacles
of human creativity and logic.
Today, we are at a new dawn of human genetics. The last
many decades of work, by the many members of this
Society and others, were largely descriptive, yet teased
from them a set of principles of human inheritance,
many unique, such as imprinting or expansion mutations.
However, we have much hard work ahead to uncover the
full logic of human genetic inheritance. Indeed, we need
our Principia Genetica with a logical foundation such that
any new inherited phenomena can be described in these
terms. In this new phase in human genetics, we need to
expand our understanding of genetic biology and increas-
ingly focus on its mechanisms. I strongly believe that only
from such very fundamental understanding will appear
the compelling ‘‘translations of knowledge’’ for tomorrow.
And that is my main message to you today. In my talk
today, I will focus on the practice of genetics in the
genomic age; genetic disease and personalized medicine;
and my own opinions and thoughts on the nature of the
gene and human diversity.
Genetics by Sequence—Human Genetics
in the Genomic Age
We no longer do human genetics by breeding but through
the DNA sequence. The classical disadvantages of working
with humans as a genetic system, small numbers of
offspring and the inability to perform controlled crosses,
have been demolished in our genome world. From 1993
to the present, international collaborative projects
such as the Human Genome Project and the HapMap,
ENCODE, Structural Variation, and 1000 Genomes pro-
jects have altered our ability to probe the human genome
efﬁciently. I have no doubt that many more such projects
will follow. But what did we seek to understand from all of
this data? What new principles did we learn?
There is absolutely no doubt that we have profoundly
altered our understanding of the human genome and
how altering its functions leads to variation in phenotypes.
First, we now know that humans, indeed all mammals,
have a small repertoire of genes whosemolecular functions
can be modulated in numerous ways. Second, the struc-
tural and functional diversity of RNA is entirely new and
astounding. Third, and an unanticipated genomic feature,
the widespread conservation of noncoding DNA inThe Ameriamounts greater than that in coding DNA is both real
and largely unexplained. Fourth, we now know of perva-
sive transcription across the genome whose meaning is
elusive. Finally, there is abundant polymorphism, in
SNPs (single nucleotide polymorphisms) and CNVs (copy
number polymorphisms), to convince even the skeptic of
their widespread genetic impact. Indeed, we have been
surprised and astounded by almost every feature of our
genome’s structure and function. And there is no doubt
in my mind that we are in store for many more surprises.
Sequence-based biology and genetics is only beginning,
and in the years ahead, according to Eric Lander,5 we will
wish to learn all sequence in the human genome, all
human genetic variation and its relationship to disease,
all functional elements in the genome, and all signatures
of cellular response. To these aims I would add: know
how to modulate all genes and how to predict functional
effects. These are grand and difﬁcult feats to be sure, but
they are problems worth every ounce of our attention
and effort. Understanding the central logic of how infor-
mation is stored in our genomes and how it plays out its
role in normal physiology and disease is our future science.
Genetic Disease and Personalized Medicine
The central feature of genetics is the ability to predict
phenotype based on genotype, once the details are under-
stood. The promise of individualized therapies relies on
this edict. Let’s consider two successes, one old and one
new, to see how our discoveries evolve into practice,
in both cases depending crucially on basic genetics
knowledge.
In human genetics, the ABO blood group system has
played a major and classical role in our understanding of
many genetic principles, from early studies of its polymor-
phisms and inheritance, to genes that modify cell surface
expression, to the biochemical basis of red cell antigens.
In medicine, the ABO types have been critical to blood
transfusions ever since this therapy became widespread
during World War II. ABO genotyping is global, largely
used without a geneticist’s help, and yet, it’s the most
widely used genetic test. Intriguingly, it’s been widely
used, despite variable frequencies of the ABO alleles across
human groups and without regard to the ‘‘race’’ of either
the donor or the recipient. This is personalized medicine
at its very best, but newer, deeper understanding promises
more exciting possibilities for the future. Studies by Clau-
sen and colleagues6 have shown the practical possibility
of enzymatically reducing all red cell types to ‘‘O,’’ prom-
ising an eventual common therapy for all individuals
without regard to their genotype.
I use the ABO example to argue that the broader medical
community will utilize genetics whenever we can provide
an effective solution to a dire need. I personally found this
out, recently, in a very different part of the world. In trying
to deal with an episode of malaria in my mother in India, I
discovered that local physicians test patients forG6PD deﬁ-
ciency prior to beginning primaquine therapy. This test iscan Journal of Human Genetics 86, 302–308, March 12, 2010 303
being widely used because of need, but not one of the
physicians using it thought of it as a genetic test. Thus,
a compelling need with a clear solution is the sine qua
non of adopting personalized medicine.
My second example is from work by two of my
colleagues whose contributions, decades apart, exemplify
what the recent future is likely to be. Victor McKusick
used Marfan syndrome to highlight the many genetic
and pleiotropic features of heritable disorders of connec-
tive tissues.7 Hal Dietz, in collaboration with McKusick,
identiﬁed the gene as ﬁbrillin 1 in 1991 and subsequently
showed the Marfan phenotype to arise from molecular
deﬁciency of ﬁbrillin 1.8 However, a possible therapy for
Marfan syndrome required a second crucial genetic
insight; namely, that the phenotype arose from a conse-
quent molecular TGFb activation. This sleuthing led Hal Di-
etz to suggest a commonly available angiotensin II receptor
antagonist drug (Losartan) as likely to reduce, or even
reverse, the life-threatening aortic root enlargement, as
his recent work suggests.9 This ﬁnding may have a much
broader use in nongenetic forms of aortic aneurysms, sug-
gesting personalized medicine is not restricted to diagnosis
but widely applicable to therapy, once we understand the
molecular basis of the pathophysiology.
Human geneticists have a critical role to play if we are to
see many more successes such as these. Our community
has been involved in the mapping and elucidation of the
molecular basis of close to 4000 disorders. But there is
much unﬁnished business. We still fail to understand the
molecular basis of the thousands of remaining Mendelian
disorders: each of them is an unlearned lesson that we
could use for gaining insight into new treatments. There
is both a need, since there are still too many childhood
developmental and cognitive disorders of unknown origin,
and an opportunity, since we have the genomic tools, to
complete this task rapidly.
The Riddle of Complex Disease Inheritance
There are other classical unsolved problems as well, partic-
ularly one that has gnawed at us for the last 100 years and
ever since the birth of our discipline. The genetic architec-
ture of complex traits is not well understood even today,
and is a puzzle that Francis Galton, Karl Pearson, and
William Bateson argued over in very strong, sometimes
personal, terms in the 1910s (Mendelian-Biometrical
debate).10 The vigor of their arguments challenged the
basic understanding of the nature of inheritance, as to
whether the logic of inheritance was primarily from rare
mutations of large effects (Mendelian) or whether small
additive effects of many genes (Biometrical) was the
norm. Then, biometricians thought rare mutations to be
inconsequential in evolution while Mendelians argued
the small effects to be of environmental origin and of no
importance to heredity. Although the early geneticists
understood the nature of the problem, they clearly did
not have the tools to crack it open or resolve these ques-
tions.11 But, it is now time to focus intensely on this304 The American Journal of Human Genetics 86, 302–308, March 1task, because its solution is central to our understanding
of how information is encoded in our genomes and how
it is compromised in human disease. Today, once again,
we appear to have two extreme notions of human inheri-
tance: one that of a single gene and the other that of an
inﬁnite number of genes. We need solutions to the vast
discontinuity that lies in between these two ‘‘models’’
since, in my view, that understanding will be central
to how we might approach therapies for multifactorial
defects.
Over the past two years we have made some progress in
identifying many common polymorphisms that inﬂuence
the risk of common disease. Some will disagree with me
and claim dramatic progress, but this depends on whether
we look back at the start or look forward to our destination.
Nevertheless, there are intense debates, much like the ones
Galton-Pearson-Bateson had, on the importance of the
ﬁndings and their meaning for common diseases. Current
research on mapping common disorder genes by genome-
wide association studies (GWAS) have had ﬁve major ﬁnd-
ings: (1) each complex trait or disease has contributions
from many genes with highly polymorphic effects; (2)
there are often multiple, independent effects at each locus;
(3) genetic effects are mostly small; (4) there is little
evidence of locus interactions; and (5) there is a signiﬁcant
role for noncoding variants. These results raise intriguing
questions: Is the widespread human polymorphism the
basis for these traits? How much of this variation is under
natural selection? What is the diversity of sequence varia-
tion and their effects at any one such locus, and does it
involve only one gene? Does the high fraction of noncod-
ing variants suggest mostly regulatory than structural vari-
ation? How do so many variants across the genome collab-
orate to affect a phenotype? Admittedly, the knowledge at
this stage is incomplete. Some have objected to the utility
of GWAS since they cannot adequately explain anywhere
near 100% of the trait variation or disease risk. This
remains an important conundrum; however, this is not
an excuse for not forging ahead with understanding dis-
ease pathophysiology that each new mapped locus pro-
vides. As you will experience at this meeting, there is
a rise in our understanding of complex diseases. However,
we do need to ﬁll the big gap between mapping and iden-
tifying the gene and its disease mechanism: this remains
the central task for human genetics to prosper.
The challenge in understanding mechanisms in com-
plex diseases, in my opinion, revolves around the hypoth-
esis that humans have a much greater disease burden that
arises from regulatory than structural variation. In other
words, our disorders are those of protein quantity than
protein quality. Compounding this challenge is the
enigma of how small the genetic effects can be. The small-
ness of the effect is constrained by development and
natural selection but also does not distinguish between
a smaller effect in everyone versus a larger effect in a subset
of individuals. These two contrasting scenarios suggest
different mechanisms and different implications for2, 2010
eventual therapies. The smallness of the effect may make
predictions of disease risk poor but is no guide to the utility
of any therapy we can fashion from the identiﬁed target.
So, it is armed with this knowledge that many scientists,
as well as the lay public, have gotten interested in disease
phenotype prediction in individual genomes.
Personal Genomics and Phenotype Prediction
The ﬁrst two recognized individuals to have their genomes
sequenced are J. Craig Venter12 and James D. Watson.13
Their genomes are publicly available, have been subjected
to many analyses, and prompt us to ask: What have we
learnt from their genomes? Maynard V. Olson14 wrote,
on the completion of the Watson genome, that: ‘‘The
application of new technology to sequence the genome
of an individual yields few biological insights. Nonethe-
less, the feat heralds an era of ‘personal genomics’ based
on cheap sequencing.’’ I am sure he would have added
the caveat ‘‘so far.’’ We, as geneticists, have been in two
minds on the value of personal genomes for individualized
medicine: we know that the codes to our phenotypic
information must be embedded in these sequences, but
we are still poor at identifying them, obtaining biological
insights, or predicting disease. This duality leads to caution
on our part but does not deter all, nor should it. Misha
Angrist, a human geneticist and one of ten participants
in George Church’s Personal Genome Project (PGP), has
written15 that ‘‘.personal genomics is criticized both for
the paucity of ‘real’ information it delivers and for the
possibility of tragic consequences resulting from people
receiving ‘life-altering’ genotype and sequence data in an
unmediated way.by pretending personal genomics is still
years away, we deny people’s agency and autonomy, we
ignore reality, and we do so at our peril.’’ This is a clear
call to improve the prediction of phenotypes from indi-
vidual genomes, but how good might this be?
The primary challenge in predicting phenotype from
genotype is not sequencing technology, which is
improving very rapidly, but in understanding the myriad
variations in our genomes and their effects. The success
of individualized medicine is currently limited by our
understanding of the meaning of most sequence changes,
most of which are rare, have not been seen earlier, yet
many are not without phenotypic consequence. For
common variants, coding or noncoding, repeated observa-
tion in different individuals allows us to both compile
them and test their effects on human phenotypes in
a rigorous manner. Witness the rise in GWAS. However,
we cannot database and test all variants this way, and
this is impractical for most human populations. So, how
does one attach meaning to DNA variants generally?
Our current attempts at assessing the biological con-
sequences of a variant are crude and, primarily, involve
segregation analysis and phenotypic correlations, identi-
fying de novo mutations, testing differences in cases and
controls, searching for evolutionary conservation, and, for
some classes of proteins, looking at measured or modeledThe Ameriactivity. But we need to improve on these methods vastly.
It is not simply a matter of collecting more data and ‘‘data-
basing’’ but, rather, there is a need for a new theory that can
reliably predict what every sequence change in the genome
can lead to. In other words, we need to understand the
numerous biological codes in genomes and how they can
be compromised in disease.
One aspect of the solution is to investigate how often
any nucleotide in the genome changes and how long it
survives; i.e., estimation of the human mutation rate.
This is one of the most basic parameters of our genome,
and yet all current estimates are over four decades old.
Although we are making some headway in understanding
somatic mutation and its rates, from sequencing cancer
genomes, the data on germline mutation rates, thought
to be ~2–5 3 105 per gene per generation, are ancient,
indirect, and nonrepresentative. The primary reason for
assessing nucleotide turnover is that extant sequence vari-
ation is confounded by past and present demography. We
need to untie this knot to illuminate both human biology
and human history. We need to know the mutation rate at
the sequence level, how it varies across the genome and
across individuals, and, importantly, which variants are
kept and which discarded and why.
The second aspect is to improve the theory that allows
better recognition of genomic codes. There has been
some exciting progress in this direction. At least for
proteins, Rama Ranganathan and his colleagues at UT
Southwestern have developed ‘‘statistical coupling anal-
ysis’’ and experimental tests to identify speciﬁc residues
in a protein that provide critical function with a resolution
far above standard conservation analysis.16 Future devel-
opments in this arena can be crucial for identifying
protein-encoding mutations in human genomes in a de
novo manner. But the problem goes beyond under-
standing proteins. We have widespread conservation in
noncoding DNA, and we need to understand those bases
as well. Groundbreaking work by Eran Segal and his col-
leagues at the Weizmann Institute in Israel have shown
how mathematical modeling on the Drosophila genome
sequence, coupled with accurate experimental data on
transcription factor abundance and sequence recognition,
can accurately predict the expression pattern of the
majority of segmentation genes during ﬂy embryogen-
esis.17 It is quite possible that these kinds of analyses can
uncover the bases where genetic changes are likely to
disturb gene expression or its regulation. I expect that
these theoretical-cum-experimental approaches will be
absolutely necessary for understanding the functions of
the human genome and which sequence variations can
compromise its biology and genetics.
The Nature of the Gene and Human Diversity
The changing notions of functions, how they are coded
and how they might affect phenotypes, are likely to lead
to a great revision in our thinking of the ‘‘gene.’’ The
notion of the gene, in the minds of the public and tocan Journal of Human Genetics 86, 302–308, March 12, 2010 305
many scientists, is that of an inﬂexiblemachine with deter-
ministic outcomes. In this view, speciﬁc genotypes lead to
predetermined, ﬁxed, and speciﬁc phenotypes. Our com-
munity’s choice of the Mendelian rather than the biomet-
rical path, in our early history, has led to remarkable
achievements in understanding, but relied largely on the
biology uncovered by single gene mutations of qualitative
effect. This is the basis of our belief in prediction and the
source of medical genetic interventions. But we know,
and have known for a long time, that phenotypes do not
necessarily obey these neat patterns. In fact, the vast
majority of human phenotypes do not Mendelize: Mende-
lian inheritance of phenotypes is the exception rather than
the rule. Most phenotypes show ‘‘complex inheritance’’
and, despite being heritable and genotype dependent, are
subject to many factors that blur the direct effect of geno-
types. The multifactorial model is adequate for explaining
many genetic features of the population being a statistical
model but is poor at predicting effects in individuals since
it is not mechanistic.We need to understand themolecular
reasons for this less-than-perfect correlation. First, we need
to appreciate the large effect that simple stochastic varia-
tion in biological processes can induce on phenotypes.
One needs only to observe a pair of identical twins to
appreciate how different they can be! Second, we need to
understand how environmental differences can yield
phenotypic differences through molecular means. Third,
as Emma Whitelaw and her colleagues have shown,18
isogenic agouti mice can have markedly different coat
colors arising from methylation of a repeat element
outside the gene. We need to assess the importance of
such heritable epigenetic effects, beyond those modulated
by chromatin, and how they contribute to inheritance.19
All of these features argue that most phenotypes are not
discrete and inviolate given a genotype but are canalized
with a range of variation modulated by sequence-depen-
dent (mutation, polymorphism) and sequence-indepen-
dent (stochastic, epigenetic) effects.20 No wonder, then,
that most phenotypic inheritance is non-Mendelian, since
the effect of genes may be bothmodiﬁable and dynamic. If
generally true, then we have a very different genetic lesson
to convey to the public: the gene as an adaptable and
dynamic machine.
Our thinking of the nature of the gene signiﬁcantly
affects our thinking of human phenotypes and how they
aggregate in families and populations. The reason why
the general view of humanity, and its myriad groups, is still
stereotypical is because we view, and associate, individual
groups by their geography and phenotypes. This is true
for geneticists, biologists, and the lay public alike. Many
recent population genetic studies, in which a thousand
or more individuals have been examined for half a million
or more SNPs, have reinforced a ‘‘genes as proxies of geog-
raphy’’ scenario. Humans can now be placed into their
continental origins as well as, sometimes, smaller geo-
graphic regions.21 This determination of ‘‘ancestry,’’ an
industry of its own, is, ﬁrst, statistical (not foolproof)306 The American Journal of Human Genetics 86, 302–308, March 1and, second, depends on an admittedly artiﬁcial view
(a model) of humanity being composed of distinct and
recognizable homogeneous groups, with some exceptions
from genetic admixture. No doubt reality is more complex,
and so we need our descriptions and population genetic
analyses to be more nuanced and our deﬁnitions of
‘‘ancestry’’ contingent. Our Society has produced a task
force report on this issue to clarify both the meanings of
the term ‘‘ancestry’’ and what answers genetics can and
cannot provide.22 Importantly, genetic admixture is a
universal phenomenon recognizable in our genes when
the admixture events are recent and between individuals
from groups isolated from one another for a long time.
But, not all populations are of that sort, and human
groups lie along a spectrum from recent to ancient admix-
ture, usually between neighboring groups where genetic
differentiation is usually low. In other words, almost all
humans are likely ‘‘admixed’’ with ancestry from different
‘‘populations.’’ ‘‘Same’’ and ‘‘different’’ can be mathemati-
cally modeled and culturally imposed, but whether genetic
variation follows this edict is still, I contend, poorly
known.
Consequently, we have much to learn from a wider
sampling of humanity across the globe and not only
from its peripheries of variation (continental groups).
These future studies can better deﬁne what we mean by
‘‘ancestry’’ and at what time in the past this ancestry refers
to. Each of us has innumerable ancestors: in my case,
recent ancestry from India, ancient ancestry from Africa,
and many others from geographies and times in between.
So, what do homogeneity, admixture, and ancestry mean
in this sense, and what notions do they convey to us as
individuals and to others? Many ongoing genetic studies
search to ﬁnd and exclude individuals in that study that
are ‘‘different’’ from the others based on their genetic vari-
ation data, since otherwise their inclusion may induce
errors in the analysis. I believe that alternative methods
that explicitly allow for ‘‘ancestry’’ differences are required.
Consider that in the United States 68% of the population
classiﬁed as ‘‘non-Hispanic White’’ in 2008 is expected to
decline to 46% by 2050. The current majority is giving
way to a new, evolving, highly heterogeneous and ad-
mixed majority. This trend is worldwide. We can no longer
bend to the current assumptions of population genetic
analysis but invent new theories and methods that can
study all peoples.
There is also amajor social component to studying diver-
sity as it appears. As geneticists, genetic and phenotypic
diversity is our currency. But, outside our research, we
have much work to do to show respect for the diversity
on which our daily research depends. Donna Nelson, at
The University of Oklahoma, has done extensive work
on the academic status of women and other underrepre-
sented minorities in US university faculties.23 In the top
50 biological departments, which are representative of
where you and I work, she has demonstrated that women
are 25% of the faculty, but this ﬁgure decreases from 35%2, 2010
for Assistant Professor, to 30% for Associate Professor, to
17% for Professorial ranks. The corresponding ﬁgures for
underrepresented minorities are 7%, 4%, and 3%, respec-
tively (4% overall); for Asians, these ﬁgures are 21%,
15%, and 8%, respectively (13% overall). The Nelson
report does not have separate ﬁgures for human genetics,
but my personal experience and anecdotal data suggest
that it is perhaps not much better. The reasons for the
inequality of rank and number in academic departments,
with regards to women and other minorities, are complex
indeed and not of singular cause. Nevertheless, the situa-
tion has changed very slowly over time and remains
an impediment to attracting the best and the brightest
persons to our faculties. Each of us needs to make progress
to remove the remaining obstacles, whatever they may be;
the numbers speak for themselves that obstacles remain.
As a member of a minority group myself, I ﬁnd, despite
my personal success, the status quo hurtful and best artic-
ulated in the words of others:24
Many rivers to cross
But I can’t seem to ﬁnd my way over
Wandering I am lost
As I travel along the white cliffs of Dover
I do not want to end on a somber note. We have an
extremely bright future, with success well within our
control. There are many different kinds of science that
we can and will do. I am also conﬁdent that our work
will lead to an improved logic in human genetics. But,
we also need to make our science more open and convey
our progress and possibilities to a much wider audience
in the public.
Two years ago, I came across a photograph that showed
two people, whom I normally would not associate with
one another, one a geneticist and the other not, at a spe-
cial celebratory dinner hosted by TIME magazine. The
familiar ﬁgure was James Watson, molecular biologist
and geneticist. There is no doubt that, despite some of
his utterly negative public comments on human variation
and its consequence, Jim Watson is a central ﬁgure who
has made genetics vibrant, stronger, and whose consider-
able efforts launched the genome project. Watson, unlike
most scientists, is universally recognized by others,
including the lay public, and probably by several million
people. The second person, unknown to most of us, was
Aishwarya Rai, a Bollywood actress from India. She is
considered by some to be the world’s most, and second
most, beautiful woman! She is easily recognized in South
Asia, as well as in many countries across the Middle East,
the Far East, Africa, and South America. By one report,
she is recognized by half a billion people! This exaggerated,
even crass, difference in popularity underscores who the
broader public is, to whom we need to speak and who
the ultimate consumers of the fruits of our imagination
are. Our charge, then, is to try to educate everyone into
the grandness of our ﬁeld, what our future science can do
to help humanity, but, ﬁrst and foremost, to improve theThe Amerifundamentals of our science and our Principia Genetica
that can lead us there.Acknowledgments
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